ANTONAZZO, IPPAZIO COSIMO

ANTONAZZO, IPPAZIO COSIMO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 70 (tempo di esecuzione: 0.026 secondi).
Titolo Tipologia Data di pubblicazione Autori File
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 01 - Articolo su rivista 2016 Antonazzo I. C. +
Raphanus sativus cv. Sango sprout juice decreases diet-induced obesity in sprague dawley rats and ameliorates related disorders 01 - Articolo su rivista 2016 Antonazzo I. C. +
The Burden of Chronic Heart Failure in Primary Care in Italy 01 - Articolo su rivista 2017 Antonazzo I. C. +
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 01 - Articolo su rivista 2017 Antonazzo I. C. +
Digestibility, toxicity and metabolic effects of rapeseed and sunflower protein hydrolysates in mice 01 - Articolo su rivista 2017 Antonazzo I. C. +
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 01 - Articolo su rivista 2018 Antonazzo I. C. +
Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis 01 - Articolo su rivista 2018 Antonazzo I. C. +
Diabetes is associated with decreased migraine risk: A nationwide cohort study 01 - Articolo su rivista 2018 Antonazzo I. C. +
Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis 01 - Articolo su rivista 2018 Antonazzo I. C. +
Drug-induced Kounis syndrome: A matter of pharmacovigilance 01 - Articolo su rivista 2019 Antonazzo I. C. +
Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study 01 - Articolo su rivista 2019 Antonazzo I. +
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 01 - Articolo su rivista 2019 Antonazzo I. C. +
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System 01 - Articolo su rivista 2019 Antonazzo I. C. +
A Multidatabase study of trajectories of antidepressant use in Italy 02 - Intervento a convegno 2020 Antonazzo, ICMazzaglia, G +
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study 01 - Articolo su rivista 2020 Antonazzo I. C.Conti S.Ferrara P.Madotto F.Mantovani L. G.Mazzaglia G. +
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 01 - Articolo su rivista 2020 Antonazzo I. C. +
Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements 01 - Articolo su rivista 2020 Antonazzo I. C. +
Patterns and trends of idarucizumab use in an Italian region: a probabilistic record-linkage approach in a real-life setting 02 - Intervento a convegno 2020 Antonazzo,ICMazzaglia, G +